Goldman Sachs Keeps Their Buy Rating on Intuitive Surgical (ISRG)
In a report released today, David Roman from Goldman Sachs maintained a Buy rating on Intuitive Surgical, with a price target of $609.00.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Roman covers the Healthcare sector, focusing on stocks such as Omada Health, Inc., Boston Scientific, and Insulet. According to TipRanks, Roman has an average return of -4.9% and a 37.65% success rate on recommended stocks.
In addition to Goldman Sachs, Intuitive Surgical also received a Buy from Citi’s Joanne Wuensch in a report issued yesterday. However, on April 6, Evercore ISI maintained a Hold rating on Intuitive Surgical (NASDAQ: ISRG).
Based on Intuitive Surgical’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.87 billion and a net profit of $794.8 million. In comparison, last year the company earned a revenue of $2.41 billion and had a net profit of $685.7 million
Read More on ISRG:
Disclaimer & DisclosureReport an Issue
- Intuitive Surgical price target lowered to $480 from $550 at Evercore ISI
- Private Markets: Kraken pauses IPO plans, Quince raises $500M
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors
- Intuitive Surgical: Stapler Reload Recall Seen as Contained, Buy Rating Reaffirmed
- Intuitive Surgical recalls curved-tip surgical staplers, says FDA
